Brean Capital Provides Key Takeaways On Horizon Pharma Following Meeting With Management
In a research report released today, Brean Capital analyst Difei Yang reiterated a Buy rating on Horizon Pharma (NASDAQ:HZNP) with a price target of $18, which represents a potential upside of 26% from where the stock is currently trading.
Yang wrote, “We met with CFO Paul Hoelscher and Chief Commercial Officer John Kody one on one during the JPM conference this week. Our key takeaways are: 1). The company is planning to expand the current portfolio from 5 products to 8-10 products; 2). We gained further confidence that Duexis and Vimovo being put on the exclusion list is likely to be a non event; and 3). Pipeline opportunity, Actimmune for the treatment of Friedreich’s Ataxia (FA), is not priced in the current shares.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Difei Yang has a total average return of 1.4% and a 53.8% success rate. Yang has a 0.3% average return when recommending HZNP, and is ranked #2002 out of 3426 analysts.